Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Change in Cash (2016 - 2025)

Neuroone Medical Technologies' Change in Cash history spans 14 years, with the latest figure at -$3.0 million for Q4 2025.

  • For Q4 2025, Change in Cash fell 823.81% year-over-year to -$3.0 million; the TTM value through Dec 2025 reached $2.4 million, up 256.94%, while the annual FY2025 figure was $5.1 million, 232.31% up from the prior year.
  • Change in Cash reached -$3.0 million in Q4 2025 per NMTC's latest filing, down from -$1.5 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $9.3 million in Q4 2021 to a low of -$3.5 million in Q4 2022.
  • Average Change in Cash over 5 years is -$178374.8, with a median of -$939973.5 recorded in 2023.
  • The largest YoY upside for Change in Cash was 924.8% in 2025 against a maximum downside of 823.81% in 2025.
  • A 5-year view of Change in Cash shows it stood at $9.3 million in 2021, then tumbled by 137.63% to -$3.5 million in 2022, then grew by 24.37% to -$2.6 million in 2023, then soared by 87.67% to -$325692.0 in 2024, then crashed by 823.81% to -$3.0 million in 2025.
  • Per Business Quant, the three most recent readings for NMTC's Change in Cash are -$3.0 million (Q4 2025), -$1.5 million (Q3 2025), and $6.7 million (Q2 2025).